Skip to content

Impact of Environmental Exposures on Tumor Risk in Subjects at Risk of Hereditary SDHx Paraganglioma

Impact of Environmental Exposures on Tumor Risk in Subjects at Risk of Hereditary SDHx-related Paragangliomas, Pilot Phase

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04481152
Acronym
PGL-EXPO-1
Enrollment
101
Registered
2020-07-22
Start date
2022-03-03
Completion date
2022-07-22
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Environmental Exposure, Genetic Predisposition, SDH Gene Mutation

Brief summary

The main objective of the pilot phase of PGLEXPO will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in SDHx-mutation carriers

Detailed description

The main objective of the pilot phase of PGLEXPO will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in SDHx-mutation carriers. Patients will be selected from subjects with a mutation in one of the SDHx genes. The cases will have developed a tumor, while the controls will be tumor-free. Controls will be matched to the cases according to sex, age and type of gene affected. Past exposures will be sought through a telephone questionnaire.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
ANSES
CollaboratorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor 2. Controls: SDHx mutation carriers with no SDHx-related tumor

Exclusion criteria

Incapacity to exercise free and informed consent for the study

Design outcomes

Primary

MeasureTime frameDescription
Feasability of the protocol of a national case/control study (PGL.EXPO2)2 yearsSuccessful pairing of 50 cases with 50 controls

Secondary

MeasureTime frameDescription
Feasibility of matching cases and controls2 yearsProportion of cases for which a control could be identified
Ease of matching cases and controls2 yearsMean number of controls matching for a case

Countries

France

Contacts

PRINCIPAL_INVESTIGATORAnne-Paule GIMENEZ-ROQUEPLO, MD, PhD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026